[15874] in Public-Access_Computer_Systems_Forum
Well positioned equity for the future?
daemon@ATHENA.MIT.EDU (David Williams)
Sun Jun 19 22:46:42 2005
Message-ID: <00ee01c5756c$250ec590$f0f35d4a@SLAOA>
From: "David Williams" <bevfraser@bettymorgan.com>
To: <oleite@mit.edu>
Date: Mon, 20 Jun 2005 01:55:40 -0600
MIME-Version: 1.0
Content-Type: multipart/alternative;
boundary="----=_NextPart_000_00EB_01C57542.3C38BD90"
This is a multi-part message in MIME format.
------=_NextPart_000_00EB_01C57542.3C38BD90
Content-Type: text/plain;
charset="iso-8859-1"
Content-Transfer-Encoding: quoted-printable
EMERGING =3D
GROWTH ALERT
Issue: 1040522
June 2005
Pingchuan Pharmaceutical Inc
Undervalued Special Situation
Symbol:
PGCN
52 Week
Range
0.15 - 4.00
Shares
Float:
25,000,000
Current
Price:
$3.08
12
Mo.Target Price
$26.00
Last 7
days gain
$2.48
Breaking News Alerts!
Big
News Expected Monday Jun 20th
Value should climb quickly!
PR Newswire (Tue, Jun 14)
Pingchuan Signs Regional Distribution Contract With Beijing
Pingchuan Tianzhi Medical Technology Development Center
EDGAR Online (Mon, May 23)
PINGCHUAN PHARMACEUTICAL INC Files SEC form 10QSB, Quarterly =3D
Report
CORPORATE PROFILE
:
Pingchuan Pharmaceutical Inc. (''PGCN'') is a =3D
modernized
pharmaceutical manufacturer with first-class medical R&D ability,
pioneered medicine products, and well-established marketing network.
Since its establishment, PGCN has focused its businesses on diabetes
medicine and its medical products. The products of PGCN include
health care products, varieties of medicine, as well as medical
apparatus. Kang Da Glycosuria Capsule is a successful product of
PGCN for treating diabetes, which was first developed in 1998 and
introduced to the market in 2001. PGCN has well-established
marketing network and sale branches, which include about 180,000
retail pharmacies/drugstores across China, agency network in major
cities like Beijing, Shanghai, Guangzhou, and Xi'an, special counter
sale at drug chain stores in key regions, residence community clinic
sale and promotion, as well as internet marketing through the
company's website. The marketing network of PGCN covers more than
50% districts of China and exports to US, Japan, Russia, and
south-eastern Asia.
About Beijing Pingchuan Tianzhi Medical Technology Development
Center
Beijing Pingchuan Tianzhi Medical Technology Development is grouped
under Harbin Pingchuan Pharmaceutical Co., Ltd. in Jan. 2000. It is
a wholly-owned subsidiary of Harbin Pingchuan Pharmaceutical
Company. TIANZHI focuses on dealing with self-produced products, as
well as dealing & distributing other medicines, health cares,
pharmaceutical apparatuses and international trade businesses
TIANZHI was authorized as the exclusive agent for the product of
Kangda'an sugar capsule in Beijing area. By the end of 2004, TIANZHI
printed out its good result that the total number of medicine
bottles sold out was 26,000 and the sales revenue in 2004 was
RMB400,000.
PGCN =3D
is
getting ready to break out. We recommend this as a VERY strong =3D
buy.
promise to hold
elections within 60 days was
not enough The sanctions include
suspension from Ecowas the recall
of ambassadors from Togo a
travel ban on the Togolese
leadership and an arms embargo
The African Union has also
condemned Mr Gnassingbe's refusal to
leave was speaking after meeting
------=_NextPart_000_00EB_01C57542.3C38BD90
Content-Type: text/html;;
charset="iso-8859-1"
Content-Transfer-Encoding: quoted-printable
<head>
<META HTTP-EQUIV=3D"Content-Type" =
CONTENT=3D"text/html;charset=3Diso-8859-1">
<html>
<style>
<!--
yfnc_modtitlew1{
width:100%;}
yfncsumdatagrid{background:#DCDCDC;width:100%;}
td{font-family:arial,helvetica,sans-serif;font-size:79%;}td{line-height:1.2=
5em;}#yfncsubtit{
width:100%;}
ygtb{font-size:18px;}-->
</style>
</head>
<body>
<table width=3D"654" border=3D"1" align=3D"center" cellpadding=3D"0" =
cellspacing=3D"0" bordercolor=3D"#000000">
<tr>
<td width=3D"650"><table width=3D"650" border=3D"0" align=3D"center" =
cellpadding=3D"3" cellspacing=3D"0">
<tr bgcolor=3D"#003399">
<td colspan=3D"2" style=3D"padding:8px" height=3D"46" =
bgcolor=3D"#008080">
<p><font size=3D"4"><strong><font color=3D"#FFFFFF">EMERGING =
GROWTH ALERT</font></strong></p></td>
</tr>
<tr>
<td bgcolor=3D"#000000" style=3D"padding:2px">
<font color=3D"#FFFFFF">Issue: 1040522</font></td>
<td bgcolor=3D"#000000" style=3D"padding:2px"><div =
align=3D"right">
<font color=3D"#FFFFFF">June 2005</font></div></td>
</tr>
<tr>
<td colspan=3D"2" style=3D"padding:10px"><div =
align=3D"left"></div>
<div align=3D"left"></div>
<table width=3D"325" border=3D"1" align=3D"right" =
cellpadding=3D"0" cellspacing=3D"0">
<tr>
<td><table width=3D"325" border=3D"1" align=3D"right" =
cellpadding=3D"3" cellspacing=3D"0">
<tr bgcolor=3D"#003399">
<td colspan=3D"2" bgcolor=3D"#008080"><b><font =
color=3D"#FFFFFF">
Pingchuan Pharmaceutical Inc</font> </b>
<font color=3D"#FFFFFF" size=3D"2" face=3D"Arial, Helvetica, =
sans-serif">
<strong><br>
Undervalued Special Situation</strong></font></td>
</tr>
<tr>
<td width=3D"53%"><font size=3D"2" face=3D"Arial, =
Helvetica, sans-serif">
Sy<b></b>mbol: </font></td>
<td width=3D"47%"><b><em>
<font size=3D"2" face=3D"Arial, Helvetica, =
sans-serif">PGCN</font></b></td>
</tr>
<tr>
<td><font size=3D"2" face=3D"Arial, Helvetica, =
sans-serif">52 Week
Range</font></td>
<td>0.15 - 4.00</td>
</tr>
<tr>
<td><font size=3D"2" face=3D"Arial, Helvetica, =
sans-serif">Sha<b></b>res
Float: </font></td>
<td><font size=3D"2" face=3D"Arial, Helvetica, =
sans-serif">
25,000,000</font></td>
</tr>
<tr>
<td><font size=3D"2" face=3D"Arial, Helvetica, =
sans-serif">Current
Price:</font></td>
<td> <font size=3D"2" face=3D"Arial, Helvetica, =
sans-serif"><strong>
$3.08</strong></font></td>
</tr>
<tr>
<td><font size=3D"2" face=3D"Arial, Helvetica, =
sans-serif">12
Mo.Target Price</font></td>
<td><font size=3D"2" face=3D"Arial, Helvetica, =
sans-serif">$26.00</font></td>
</tr>
<tr>
<td><font size=3D"2" face=3D"Arial, Helvetica, =
sans-serif"> Last 7
days gain</font></td>
<td>$2.48</td>
</tr>
</table></td>
</tr>
</table>
<p><em><font color=3D"#CC0000" size=3D"4" face=3D"Arial, =
Helvetica, sans-serif"><strong>
Breaking News Alerts!</strong></font></em></p>
<p><em><strong>
<font face=3D"Arial, Helvetica, sans-serif" color=3D"#CC0000" =
size=3D"3">Big
News Expected Monday Jun 20th<br>
Value should climb quickly!</font></strong></p>
<p><b>PR Newswire (Tue, Jun 14)</b><br>
Pingchuan Signs Regional Distribution Contract With Beijing
Pingchuan Tianzhi Medical Technology Development Center <br>
<br>
<b>EDGAR Online (Mon, May 23)</b><font face=3D"Arial, Helvetica, =
sans-serif" size=3D"2"><br>
PINGCHUAN PHARMACEUTICAL INC Files SEC form 10QSB, Quarterly =
Report</font></p>
<p><font face=3D"Arial, Helvetica, sans-serif"><strong><font =
color=3D"#003399"><u>
CORPORATE PROFILE</u></font></strong></font>
<u><font color=3D"#003399" size=3D"2" face=3D"Arial, Helvetica, =
sans-serif">
:</font></u><font size=3D"2" face=3D"Arial, Helvetica, sans-serif"><br>
Pingchuan Pharmaceutical Inc. (''PGCN'') is a =
modernized
pharmaceutical manufacturer with first-class medical R&D ability,
pioneered medicine products, and well-established marketing network.
Since its establishment, PGCN has focused its businesses on diabetes
medicine and its medical products. The products of PGCN include
health care products, varieties of medicine, as well as medical
apparatus. Kang Da Glycosuria Capsule is a successful product of
PGCN for treating diabetes, which was first developed in 1998 and
introduced to the market in 2001. PGCN has well-established
marketing network and sale branches, which include about 180,000
retail pharmacies/drugstores across China, agency network in major
cities like Beijing, Shanghai, Guangzhou, and Xi'an, special counter
sale at drug chain stores in key regions, residence community clinic
sale and promotion, as well as internet marketing through the
company's website. The marketing network of PGCN covers more than
50% districts of China and exports to US, Japan, Russia, and
south-eastern Asia.<br>
<br>
About Beijing Pingchuan Tianzhi Medical Technology Development
Center<br>
<br>
Beijing Pingchuan Tianzhi Medical Technology Development is grouped
under Harbin Pingchuan Pharmaceutical Co., Ltd. in Jan. 2000. It is
a wholly-owned subsidiary of Harbin Pingchuan Pharmaceutical
Company. TIANZHI focuses on dealing with self-produced products, as
well as dealing & distributing other medicines, health cares,
pharmaceutical apparatuses and international trade businesses
TIANZHI was authorized as the exclusive agent for the product of
Kangda'an sugar capsule in Beijing area. By the end of 2004, TIANZHI
printed out its good result that the total number of medicine
bottles sold out was 26,000 and the sales revenue in 2004 was
RMB400,000.<br>
<br>
<br>
</font><b><font size=3D"2" face=3D"Arial, Helvetica, sans-serif">PGCN =
is
getting ready to break out. We recommend this as a VERY strong =
buy.</font></b></li></p>
</ol> </em> </td>
</tr>
<tr>
<td colspan=3D"2" style=3D"padding:15px"><p =
align=3D"justify"> </p></td>
</tr>
</table></td>
</tr>
<tr>
<td colspan=3D"2" style=3D"padding:15px" height=3D"106"><p =
align=3D"justify"> </p>
<p align=3D"justify"> </p>
<p align=3D"justify"> </p>
<p align=3D"justify"> </p>
<p align=3D"justify"> </p>
<p align=3D"justify"> </p>
<p align=3D"justify"> </p>
<p align=3D"justify"> </p>
<p align=3D"justify"> </p>
<p align=3D"justify">promise to hold
elections within 60 days was
not enough The sanctions include
suspension from Ecowas the recall
of ambassadors from Togo a
travel ban on the Togolese
leadership and an arms embargo
The African Union has also
condemned Mr Gnassingbe's refusal to
leave was speaking after meeting</p></td>
</tr>
</table>
<br></body>
</html>
------=_NextPart_000_00EB_01C57542.3C38BD90--
